TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Study is designed to explore whether the introduction of Thiotepa, to the pre autologous
stem-cell transplantation (ASCT) conditioning will reduce toxicity and thus improve outcome
following transplantation in up to 24 patients with malignant lymphoma including both
non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma ( HL) improving toxicity profile ,
reducing side effects while potentially improving the antitumor response. Specifically,we
speculate that using the novel Thiotepa based TEAM consisted of THIOTEPA 5mg/kg on days -7-6,
etoposide 200 mg/m2 , Cytosar (ARA-C) 200 mg/m2 on days -5,-4, -3, -2 and melphalan 140 mg/m2
on day -1, pre transplantation conditioning regimen may allow transplantation with lower
transplant related toxicity and thus improve outcome in this setting. Toward this aim the
impact on toxicity profile ,engraftment and disease control will be assessed.